Woman and Man | 18 years and more
- | Country :
- France
- | organs :
- Leucémies chroniques
- | Specialty :
- Thérapies Ciblées
Extract
An open-label, randomized study of dasatinib vs. high-dose (800 mg) imatinib in the treatment of subjects with chronic phase chronic myeloid leukemia who have had a suboptimal response after at least 3 months of therapy with 400 mg imatinib.
Scientific Abstract
en cours d'intégration;